Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:43:45.828Z.
Calculation as of: 2026-10-06T19:43:45.828Z.
Quote observation: 2026-10-06T19:39:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PEG RATIO
N/A
Vogenx Inc.
Market Cap
$224.99M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Vogenx Inc. (VOGX) | $224.99M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.88M | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.77M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.02M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.31M | N/A |
| BioAge Labs Inc. (BIOA)vs › | $231.49M | N/A |
| InflaRx N.V. (IFRX)vs › | $231.99M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.96M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $234.48M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
